With our sole focus on kidney diseases, we aspire to be the world's leading precision medicine kidney company. There are few therapeutic options that target the underlying cause of disease. Our solution to address this growing need is applying precision medicine to pioneer the discovery, development and commercialization of kidney disease treatments. Historically, there has been a 'one size fits all' approach to treating kidney disease. This has been due to a lack of understanding of kidney disease at the molecular level. Thanks to a growing understanding of kidney biology and genetics, including pioneering research by the founders of Goldfinch, the scientific community is starting to understand the heterogeneity inherent in kidney disease.